Daraxonrasib's NDA is accepted with a National Priority Voucher — which puts an FDA decision in weeks, not mid-2027

What happened

Revolution Medicines announced on 22 July 2026, in a release on its investor-relations newsroom carried over GlobeNewswire, that the U.S. Food and Drug Administration "accepted for review the company's New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)." ^[1]

The same release settles the regulatory pathway: daraxonrasib "was selected for the FDA Commissioner's National Priority Voucher pilot program, which is designed to accelerate the review of medicines that address key national health priorities." ^[1] The FDA had previously granted the asset Breakthrough Therapy Designation and Orphan Drug Designation in this indication. ^[1] No target action date is published — not by the company, not by the agency.

The voucher is a date, and the date is not mid-2027

Naming a regulatory pathway is not the finding. The finding is what it does to the calendar.

The FDA describes the Commissioner's National Priority Voucher as an "ultra-fast timeline — 1-2 months target vs. 6+ months," delivered through enhanced pre-submission communications, expedited rolling review, and a multidisciplinary "tumor board-style" discussion between the review team and senior agency leadership. ^[2]

Applied to this file: the NDA was accepted on 22 July 2026 ^[1]. On the voucher's target timeline, an FDA action on daraxonrasib in previously treated metastatic PDAC plausibly lands between late August and the end of September 2026. On a conventional oncology review clock, the same application would have been decided around the middle of 2027.

Three caveats, and they are load-bearing. The FDA states 1–2 months as a target, not a statutory deadline ^[2]. Neither Revolution Medicines nor the agency has published a target action date for this application ^[1]. And the programme measures its clock from submission of the application rather than from acceptance, a date the release does not give separately ^[1][2]. Prognyx therefore publishes a range, not a date.

What the range changes: any competitive plan built on daraxonrasib being a 2027 commercial event is roughly nine months out of position. The Royalty Pharma milestones that trigger on approval — a further $250 million of synthetic royalty and the first $250 million loan tranche ^[5] — move onto the same compressed schedule. So does the point at which a pretreated-PDAC label starts constraining trial recruitment for competing assets in the same line.

Daraxonrasib (RMC-6236; ChEMBL CHEMBL6168538) is an oral RAS(ON) multi-selective inhibitor — designed to drug the active, GTP-bound ("ON") state of RAS across mutant variants rather than one allele at a time. ^[4][12]

The data behind the filing

The submission follows the pivotal RASolute 302 trial. On April 13, 2026, Revolution Medicines announced that RASolute 302 — a global Phase 3 study of daraxonrasib monotherapy in previously treated metastatic PDAC, enrolling across the U.S., EU and Japan — met all primary and key secondary endpoints, including progression-free survival and overall survival. ^[5][6] The topline is, so far, qualitative: the specific medians, hazard ratios, confidence intervals, patient numbers and RAS-mutation subgroup splits from RASolute 302 are not in the public record Prognyx reviewed, The trial is registered as NCT06625320: 500 participants (actual), active but no longer recruiting as of the 29 May 2026 update. ^[3] Its two primary endpoints are progression-free survival and overall survival in the RAS G12-mutant population, with PFS and OS in the whole enrolled population as secondary endpoints. ^[1][3]

What is public is the earlier monotherapy dataset that set the Phase 3 dose. At 300 mg once daily — the RASolute 302 dose — the July 23, 2024 cutoff showed median PFS of 8.8 months (95% CI 8.5–NE) in PDAC patients with a KRAS G12X mutation, with OS not estimable, and 8.5 months in patients with any RAS mutation. ^[4] Separately, the earlier EORTC-NCI-AACR dose-ranging dataset across a 160–300 mg range put median PFS at 8.5 months (95% CI 5.3–11.7) and median OS at 14.5 months (95% CI 8.8–NE) in KRAS G12X patients, with any-RAS patients at 7.6 months PFS and 14.5 months OS. ^[4] These are earlier monotherapy figures — not the RASolute 302 result — and should not be read as the pivotal numbers. Safety in those datasets was manageable: rash and GI toxicity dominated, mostly Grade 1–2, with no Grade 3+ treatment-related adverse event in more than 10% of patients and no discontinuations for TRAEs. ^[4]

Why it matters

The strategic point is coverage. Roughly 50% of PDAC patients present with a KRAS G12D mutation, per figures cited in a July 2026 preclinical EMBO Journal study — not a dedicated epidemiology source. ^[11] A G12D-selective or G12C-selective agent addresses one slice of that population; daraxonrasib's multi-selective RAS(ON) mechanism reaches the broader G12X / any-RAS population in a single oral drug. That is why the two details still missing from the reported filing — the precise RAS mutations covered and whether the label is confined to "previously treated" — will be the most consequential facts when the NDA specifics surface. Revolution Medicines has separately been planning first-line metastatic and adjuvant (resectable) PDAC registrational trials, so a pretreated indication would be the first of several intended lines. ^[6]

Who gained

Royalty Pharma. Under the June 2025 agreement, Royalty Pharma committed up to $2 billion to daraxonrasib — a synthetic royalty of up to $1.25 billion plus a senior secured loan of up to $750 million — funding $250 million upfront. ^[5] The April 13, 2026 positive readout triggered a further $250 million; another $250 million of synthetic royalty unlocks on FDA approval in metastatic PDAC, and the first $250 million loan tranche must be drawn following that approval. ^[5] Royalty Pharma earns tiered royalties of 4.55% on the first $2B of net sales, 2.50% on $2–4B and 1.00% on $4–8B, scaling up to 7.80% / 4.55% / 2.40% if the full remaining $750M synthetic royalty is drawn. ^[5] The structure is worth reading closely: the cash-flow trigger is approval, not acceptance — the reported NDA milestone moves nothing on the financing schedule until the FDA acts on the file.

Who is exposed

Anyone betting on single-allele RAS inhibition in PDAC now faces a multi-selective agent reportedly at the filing stage in the pretreated setting. Revolution Medicines itself runs two allele-selective RAS(ON) inhibitors — elironrasib (RMC-6291, G12C-selective) and zoldonrasib (RMC-9805, G12D-selective). ^[4] Prognyx reads that portfolio design as positioning daraxonrasib as the broad-RAS backbone and the selective agents as combination or later-line partners — an interpretation, not a company statement.

The scientific caveat sits in the same window. A July 2026 preclinical EMBO Journal study reports that CDK8 remodels the tumor microenvironment and drives resistance to both KRAS G12D inhibitors and daraxonrasib in PDAC models — an early, laboratory-stage flag that durability may hinge on combinations, not monotherapy. ^[11] Daraxonrasib in advanced RAS-mutated PDAC is also the subject of NEJM correspondence published July 1, 2026, whose content Prognyx did not review beyond its title and DOI. ^[10]

What to watch (with dates)

• FDA action, late August to end-September 2026 (Prognyx range). No target action date is published. ^[1] The range is derived from the FDA's own 1–2 month CNPV target applied to the 22 July 2026 acceptance ^[1][2] — a target, not a deadline. This is the event that flips the Royalty Pharma milestones and, if positive, the label.
• Review pathway: settled. Daraxonrasib was selected for the Commissioner's National Priority Voucher pilot programme, on top of Breakthrough Therapy and Orphan Drug Designations already granted in this indication. ^[1]
• EMA accelerated (phased) review: opened around July 7, 2026 (EMA, corroborated by Reuters on 2026-07-07) — a parallel path in metastatic PDAC, not an approval. ^[8][9]
• Expanded access: the FDA issued a "safe to proceed" letter around May 1, 2026 permitting an expanded access treatment protocol for daraxonrasib in pancreatic cancer. ^[7]
• NSCLC: RASolve 301, a Phase 3 of daraxonrasib versus docetaxel in previously treated RAS-mutant NSCLC, was activating sites as of May 2025. ^[6]
• Earlier lines: first-line and adjuvant PDAC registrational trials were planned for 2H 2025; their current initiation status is not confirmed in the sources reviewed. ^[6]

The now-what

For a biotech operator with a RAS or PDAC program, three moves are on the table.

1. Re-test differentiation on mutation coverage and line of therapy. Daraxonrasib is under review for broad-RAS use in the pretreated setting, on a voucher timeline; the open lanes are first-line, adjuvant, allele-specific niches, and combinations that answer the preclinical CDK8 / tumor-microenvironment resistance axis. ^[11]

2. Wait for the label before sizing the white space. The RAS mutations and population in the eventual indication define the addressable market; until the NDA specifics are public, this is unresolved and should not be modeled as pan-RAS by default.

3. Benchmark the financing. The Royalty Pharma structure — up to $2B tied to approval milestones and tiered to $8B of sales — is a live template for how a de-risked RAS asset gets funded without dilution, and a yardstick for any comparable deal. ^[5]

Verdict: threat level high for allele-specific PDAC programmes, and the window is measured in weeks rather than quarters. Acceptance advances the file, not the approval — but a National Priority Voucher compresses the interval between the two to an FDA target of one to two months ^[1][2], with the EMA phased review running in parallel ^[8][9]. Any plan whose first daraxonrasib decision point sits in 2027 needs re-dating this quarter.